CD274 and breast cancer: Another combination study of anti-PD-L1 (durvalumab) plus anti-CTLA-4 (tremelimumab) in a small group of 28 high-risk BC cisplatin-ineligible patients (NCT02812420) demonstrated a pathological complete response of 37.5% and downstaging to pT1 or less in 58% of patients [41], making a combination of PD-L1 and CTLA-4 blockade a promising approach in BC.